Uterine Cancer—Health Professional Version
Most uterine cancers start in the endometrium, which is called endometrial cancer. Uterine sarcoma is a form of uterine cancer of the muscle and tissue that support the uterus. Find evidence-based information on uterine cancer treatment, causes and prevention, screening, research, genetics, and statistics.
Uterine Cancer Treatment
-
Endometrial Cancer Treatment (PDQ®)
Get detailed information on endometrial cancer, including symptoms, diagnosis, prognosis, staging, and treatment for early- and advanced-stage disease, in this summary for clinicians.
-
Uterine Sarcoma Treatment (PDQ®)
Get detailed information on newly diagnosed and recurrent uterine sarcoma, including surgery, radiation therapy, chemotherapy, and other treatment options, in this summary for clinicians.
-
Drugs Approved for Endometrial Cancer
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for endometrial cancer. The list includes generic names and brand names.
Treatment Clinical Trials for Uterine Cancer
Prevention and Screening for Uterine Cancer
-
Endometrial Cancer Prevention (PDQ®)
Get detailed information on endometrial cancer risk factors and prevention strategies in this summary for clinicians.
-
Endometrial Cancer Screening (PDQ®)
Get detailed information on endometrial cancer screening, including potential harms, in this summary for clinicians.
-
Menopausal Hormone Therapy and Cancer
Learn about menopausal hormone therapy, including its effects on the body and potential benefits and risks.
-
Oral Contraceptives and Cancer Risk
Learn what the research says about cancer risk associated with the use of birth control pills.
Genetics Information
-
Genetics of Breast and Gynecologic Cancers (PDQ®)
Get comprehensive information on hereditary breast and gynecologic cancer syndromes and associated genes, including BRCA1/BRCA2, Lynch syndrome, PALB2, and others, in this clinician summary.
-
Rhabdoid Tumor Predisposition Syndrome Type 2 (PDQ®)
Learn about the clinical features and management of Rhabdoid Tumor Predisposition Syndrome Type 2 (RTPS2), a hereditary cancer syndrome associated with the SMARCA4 gene.